Lumos Diagnostics Secures Key U.S. Reimbursement Milestones for FebriDx®

Lumos Diagnostics Holdings Ltd. ( (AU:LDX) ) has issued an update.

Lumos Diagnostics has achieved significant milestones in securing U.S. reimbursement for its FebriDx® test, a rapid diagnostic tool for respiratory infections. The company has obtained reimbursement coverage with two Medicare Administration Contractors, setting a reimbursement rate of $41.38 per test effective April 2025, and is progressing negotiations with additional contractors. This development is expected to facilitate broader adoption by private insurers, enhancing FebriDx’s role in improving clinical outcomes and reducing unnecessary antibiotic prescriptions.

More about Lumos Diagnostics Holdings Ltd.

Lumos Diagnostics Holdings Ltd. is a leader in rapid, point-of-care diagnostic technologies. The company focuses on developing diagnostic solutions that differentiate between bacterial and non-bacterial acute respiratory infections, exemplified by their product FebriDx®, which provides results in approximately 10 minutes.

YTD Price Performance: -45.00%

Average Trading Volume: 1,397,283

Technical Sentiment Signal: Buy

Current Market Cap: A$16.47M

Learn more about LDX stock on TipRanks’ Stock Analysis page.